Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)
52.69 x 1 54.95 x 1
Post-market by (Cboe BZX)
54.91 +0.41 (+0.75%) 03/27/25 [NASDAQ]
52.69 x 1 54.95 x 1
Post-market 54.92 +0.01 (+0.02%) 18:03 ET
Quote Overview for Thu, Mar 27th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
54.70
Day High
55.05
Open 54.77
Previous Close 54.50 54.50
Volume 1,320,400 1,320,400
Avg Vol 3,010,410 3,010,410
Stochastic %K 8.23% 8.23%
Weighted Alpha +12.99 +12.99
5-Day Change -2.88 (-4.98%) -2.88 (-4.98%)
52-Week Range 45.22 - 60.12 45.22 - 60.12
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 138,312,544
  • Shares Outstanding, K 2,537,845
  • Annual Sales, $ 47,922 M
  • Annual Income, $ 6,016 M
  • EBIT $ 10,112 M
  • EBITDA $ 13,993 M
  • 60-Month Beta 0.58
  • Price/Sales 3.17
  • Price/Cash Flow 10.40
  • Price/Book 1.67

Options Overview Details

View History
  • Implied Volatility 27.89% ( +0.33%)
  • Historical Volatility 22.20%
  • IV Percentile 75%
  • IV Rank 45.95%
  • IV High 39.81% on 04/24/24
  • IV Low 17.75% on 05/13/24
  • Put/Call Vol Ratio 0.17
  • Today's Volume 116
  • Volume Avg (30-Day) 1,882
  • Put/Call OI Ratio 1.24
  • Today's Open Interest 35,273
  • Open Int (30-Day) 32,606

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.87
  • Number of Estimates 7
  • High Estimate 0.90
  • Low Estimate 0.84
  • Prior Year 0.96
  • Growth Rate Est. (year over year) -9.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.98 +1.72%
on 03/26/25
Period Open: 54.14
60.12 -8.66%
on 03/10/25
+0.77 (+1.42%)
since 02/27/25
3-Month
47.79 +14.90%
on 01/03/25
Period Open: 48.73
60.12 -8.66%
on 03/10/25
+6.18 (+12.68%)
since 12/27/24
52-Week
45.22 +21.43%
on 04/18/24
Period Open: 49.54
60.12 -8.66%
on 03/10/25
+5.37 (+10.84%)
since 03/27/24

Most Recent Stories

More News
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease (“CD”), and Novartis’ NVS Fabhalta for its third indication, C3...

AZN : 72.84 (+0.17%)
JNJ : 163.13 (+0.87%)
NVS : 111.40 (+1.14%)
PFE : 25.01 (-0.79%)
SNY : 54.91 (+0.75%)
2 Small-Cap Stocks Set to Skyrocket With Upside Potential Between 36% and 102%

These smaller stocks may carry more risk, but they also carry greater reward potential.

NVDA : 111.43 (-2.05%)
BAYRY : 6.1400 (+0.33%)
RXRX : 5.97 (-3.24%)
ARDX : 5.14 (+1.98%)
RHHBY : 42.3500 (-0.66%)
SNY : 54.91 (+0.75%)
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug

Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to acquire the latter’s investigational bispecific antibody DR-0201.DR-0201 is...

NVS : 111.40 (+1.14%)
REGN : 635.83 (-0.67%)
PFE : 25.01 (-0.79%)
SNY : 54.91 (+0.75%)
AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies

Amgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET program that is evaluating the investigational anti-OX40 therapy rocatinlimab...

REGN : 635.83 (-0.67%)
AMGN : 305.77 (+0.02%)
SNY : 54.91 (+0.75%)
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

REGN : 635.83 (-0.67%)
SNY : 54.91 (+0.75%)
Novavax Lands Wall Street 'Buy' Rating After Q4 Results, Retail Bulls Eye More Upside On Sanofi Partnership

The company expects to generate $300 million to $350 million in adjusted licensing, royalties, and other revenue in 2025.

NVAX : 7.26 (-1.76%)
SNY : 54.91 (+0.75%)
Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.

NVO : 70.16 (-2.19%)
LLY : 821.67 (-0.62%)
REGN : 635.83 (-0.67%)
SNY : 54.91 (+0.75%)
Novavax Retail Traders Stay Bullish Ahead Of Q4 Print Even As RFK Jr's HHS Leadership Causes Ripples

Kennedy, a longtime vaccine skeptic, now oversees HHS decisions that could impact vaccine makers, making his leadership a wild card for Novavax.

NVAX : 7.26 (-1.76%)
SNY : 54.91 (+0.75%)
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application (sBLA) seeking approval for Dupixent for treating bullous pemphigoid (BP), a chronic,...

ALNY : 271.02 (+0.67%)
GILD : 111.16 (+1.73%)
REGN : 635.83 (-0.67%)
SNY : 54.91 (+0.75%)
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs

This week, Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug Adcetris and a tablet formulation of Roche’s RHHBY spinal muscular atrophy...

NVS : 111.40 (+1.14%)
ABBV : 202.72 (+0.71%)
RHHBY : 42.3500 (-0.66%)
PFE : 25.01 (-0.79%)
SNY : 54.91 (+0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme,...

See More

Key Turning Points

3rd Resistance Point 55.42
2nd Resistance Point 55.24
1st Resistance Point 55.07
Last Price 54.91
1st Support Level 54.72
2nd Support Level 54.54
3rd Support Level 54.37

See More

52-Week High 60.12
Last Price 54.91
Fibonacci 61.8% 54.43
Fibonacci 50% 52.67
Fibonacci 38.2% 50.91
52-Week Low 45.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies